CCI study: Diabetes patients may do better with everolimus stents

04/7/2013 | Healio

Data on 968 diabetes patients who had percutaneous coronary intervention revealed those who used paclitaxel-eluting stents had higher thrombosis rates at six and 12 months and higher mortality at one year compared with those who were treated with everolimus-eluting stents. The findings appear in Catheterization and Cardiovascular Interventions.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY